Cargando…
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521349/ https://www.ncbi.nlm.nih.gov/pubmed/36185208 http://dx.doi.org/10.3389/fonc.2022.966534 |
_version_ | 1784799818417176576 |
---|---|
author | Swami, Umang Zimmerman, Raquel Mae Nussenzveig, Roberto H. Hernandez, Edgar Javier Jo, Yeonjung Sayegh, Nicolas Wesolowski, Sergiusz Kiedrowski, Lesli A. Barata, Pedro C. Lemmon, Gordon Howard Bilen, Mehmet A. Heath, Elisabeth I. Nandagopal, Lakshminarayan Babiker, Hani M. Pal, Sumanta K. Lilly, Michael Maughan, Benjamin L. Haaland, Benjamin Yandell, Mark Sartor, Oliver Agarwal, Neeraj |
author_facet | Swami, Umang Zimmerman, Raquel Mae Nussenzveig, Roberto H. Hernandez, Edgar Javier Jo, Yeonjung Sayegh, Nicolas Wesolowski, Sergiusz Kiedrowski, Lesli A. Barata, Pedro C. Lemmon, Gordon Howard Bilen, Mehmet A. Heath, Elisabeth I. Nandagopal, Lakshminarayan Babiker, Hani M. Pal, Sumanta K. Lilly, Michael Maughan, Benjamin L. Haaland, Benjamin Yandell, Mark Sartor, Oliver Agarwal, Neeraj |
author_sort | Swami, Umang |
collection | PubMed |
description | BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained by distinct genomic landscapes of BRCA1 versus BRCA2 co-segregating genes. In a large dataset of 7,707 men with advanced prostate cancer undergoing comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA), 614 men harbored BRCA1 and/or BRCA2 alterations. Differences in the genomic landscape of co-segregating genes was investigated by Fisher’s exact test and probabilistic graphical models (PGMs). Results demonstrated that BRCA1 was significantly associated with six other genes, while BRCA2 was not significantly associated with any gene. These findings suggest BRCA2 may be the main driver mutation, while BRCA1 mutations tend to co-segregate with mutations in other molecular pathways contributing to prostate cancer progression. These hypothesis-generating data may explain the differential response to PARP inhibition and guide towards the development of combinatorial drug regimens in those with BRCA1 mutation. |
format | Online Article Text |
id | pubmed-9521349 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95213492022-09-30 Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA Swami, Umang Zimmerman, Raquel Mae Nussenzveig, Roberto H. Hernandez, Edgar Javier Jo, Yeonjung Sayegh, Nicolas Wesolowski, Sergiusz Kiedrowski, Lesli A. Barata, Pedro C. Lemmon, Gordon Howard Bilen, Mehmet A. Heath, Elisabeth I. Nandagopal, Lakshminarayan Babiker, Hani M. Pal, Sumanta K. Lilly, Michael Maughan, Benjamin L. Haaland, Benjamin Yandell, Mark Sartor, Oliver Agarwal, Neeraj Front Oncol Oncology BRCA1-mutated prostate cancer has been shown to be less responsive to poly (ADP-ribose) polymerase (PARP) inhibitors as compared to BRCA2-mutated prostate cancer. The reason for this differential response is not clear. We hypothesized this differential sensitivity to PARP inhibitors may be explained by distinct genomic landscapes of BRCA1 versus BRCA2 co-segregating genes. In a large dataset of 7,707 men with advanced prostate cancer undergoing comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA), 614 men harbored BRCA1 and/or BRCA2 alterations. Differences in the genomic landscape of co-segregating genes was investigated by Fisher’s exact test and probabilistic graphical models (PGMs). Results demonstrated that BRCA1 was significantly associated with six other genes, while BRCA2 was not significantly associated with any gene. These findings suggest BRCA2 may be the main driver mutation, while BRCA1 mutations tend to co-segregate with mutations in other molecular pathways contributing to prostate cancer progression. These hypothesis-generating data may explain the differential response to PARP inhibition and guide towards the development of combinatorial drug regimens in those with BRCA1 mutation. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9521349/ /pubmed/36185208 http://dx.doi.org/10.3389/fonc.2022.966534 Text en Copyright © 2022 Swami, Zimmerman, Nussenzveig, Hernandez, Jo, Sayegh, Wesolowski, Kiedrowski, Barata, Lemmon, Bilen, Heath, Nandagopal, Babiker, Pal, Lilly, Maughan, Haaland, Yandell, Sartor and Agarwal https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Swami, Umang Zimmerman, Raquel Mae Nussenzveig, Roberto H. Hernandez, Edgar Javier Jo, Yeonjung Sayegh, Nicolas Wesolowski, Sergiusz Kiedrowski, Lesli A. Barata, Pedro C. Lemmon, Gordon Howard Bilen, Mehmet A. Heath, Elisabeth I. Nandagopal, Lakshminarayan Babiker, Hani M. Pal, Sumanta K. Lilly, Michael Maughan, Benjamin L. Haaland, Benjamin Yandell, Mark Sartor, Oliver Agarwal, Neeraj Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA |
title | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA |
title_full | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA |
title_fullStr | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA |
title_full_unstemmed | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA |
title_short | Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA |
title_sort | genomic landscape of advanced prostate cancer patients with brca1 versus brca2 mutations as detected by comprehensive genomic profiling of cell-free dna |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521349/ https://www.ncbi.nlm.nih.gov/pubmed/36185208 http://dx.doi.org/10.3389/fonc.2022.966534 |
work_keys_str_mv | AT swamiumang genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT zimmermanraquelmae genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT nussenzveigrobertoh genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT hernandezedgarjavier genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT joyeonjung genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT sayeghnicolas genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT wesolowskisergiusz genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT kiedrowskileslia genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT baratapedroc genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT lemmongordonhoward genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT bilenmehmeta genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT heathelisabethi genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT nandagopallakshminarayan genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT babikerhanim genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT palsumantak genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT lillymichael genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT maughanbenjaminl genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT haalandbenjamin genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT yandellmark genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT sartoroliver genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna AT agarwalneeraj genomiclandscapeofadvancedprostatecancerpatientswithbrca1versusbrca2mutationsasdetectedbycomprehensivegenomicprofilingofcellfreedna |